These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 30876800)
41. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis. Miyagaki T; Sugaya M; Suga H; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e60-7. PubMed ID: 22404649 [TBL] [Abstract][Full Text] [Related]
43. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Seto AG; Beatty X; Lynch JM; Hermreck M; Tetzlaff M; Duvic M; Jackson AL Br J Haematol; 2018 Nov; 183(3):428-444. PubMed ID: 30125933 [TBL] [Abstract][Full Text] [Related]
44. New Genetic Markers of Skin T-Cell Lymphoma Treatment. Vašků V; Fialová P; Vašků A Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540417 [TBL] [Abstract][Full Text] [Related]
45. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941 [TBL] [Abstract][Full Text] [Related]
47. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation. Kato Y; Egusa C; Maeda T; Tsuboi R J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218 [TBL] [Abstract][Full Text] [Related]
48. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. Ramelyte E; Dummer R; Guenova E Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295 [No Abstract] [Full Text] [Related]
49. Reversible resistance to apoptosis in cutaneous T cell lymphoma. Meech SJ; Edelson R; Walsh P; Norris DA; Duke RC Ann N Y Acad Sci; 2001 Sep; 941():46-58. PubMed ID: 11594582 [TBL] [Abstract][Full Text] [Related]
51. Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma. Miyagaki T; Sugaya M; Suga H; Akamata K; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S Arch Dermatol Res; 2012 Jul; 304(5):401-6. PubMed ID: 22526325 [TBL] [Abstract][Full Text] [Related]
52. Clonal disease in extracutaneous compartments in cutaneous T-cell lymphomas. A comparative study between cutaneous T-cell lymphomas and pseudo lymphomas. Dommann SN; Dommann-Scherrer CC; Dours-Zimmermann MT; Zimmermann DR; Kural-Serbes B; Burg G Arch Dermatol Res; 1996 Apr; 288(4):163-7. PubMed ID: 8967786 [TBL] [Abstract][Full Text] [Related]
53. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899 [TBL] [Abstract][Full Text] [Related]